Q4 2024 Bio Rad Laboratories Inc Earnings Call Transcript

Feb 13, 2025 / 10:00PM GMT

Release Date Price: $312.05 (-9.25%)

Transcript 10-K8-K

Key Points

Positve

Bio-Rad Laboratories Inc (BIO) successfully met its revised 2024 guidance for both revenue and operating margin.
The company achieved gross margin expansion in 2024 through productivity improvements and effective cost management.
Bio-Rad Laboratories Inc (BIO) entered into a binding offer to acquire Stilla Technologies, which is expected to enhance its digital PCR portfolio.
The Clinical Diagnostics Group saw a 3.3% increase in sales for 2024, driven by demand for quality control and blood typing products.
The company reported a significant improvement in free cash flow for 2024, reaching approximately $290 million compared to $218 million in 2023.

Negative

Net sales for the fourth quarter of 2024 declined by 2% on a reported basis, primarily due to lower sales in the Life Science segment.
The Life Science Group experienced a 12.8% decline in sales for 2024, with currency-neutral sales decreasing across all regions.
The company faced a revenue decline in its diabetes portfolio due to a reimbursement change in China, impacting Q4 gross margin.
Bio-Rad Laboratories Inc (BIO) implemented a 5% workforce reduction to align headcount with its global organization.
The company reported a net loss of $716 million for the fourth quarter of 2024, primarily due to a $977 million loss related to the fair market value of equity security holdings.

Operator

Thank you for standing by. My name is Prila, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad Fourth Quarter and Full Year 2024 Results Conference Call and webcast. (Operator Instructions)

I would now like to turn the conference over to Edward Chung, Head of Investor Relations. You may begin.

Edward Chung

Bio Rad Laboratories Inc - Vice President - Investor Relations

Thanks, operator. Good afternoon, everyone, and thank you for joining us. Today, we will review the fourth quarter and full year 2024 financial results and provide an update on key business trends for Bio-Rad.

With me on the call today are Norman Schwartz, our Chief Executive Officer; Jon DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer.

Before we begin our review, I would like to remind everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance and other

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.